Praluent International Purchase Legalities: How to Get Alirocumab Cheaper in 2026

What Is Praluent and Why Does Cost Matter?

Praluent (alirocumab) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors in the liver. Blocking PCSK9 preserves LDL receptors, which then clear more LDL-C from the bloodstream. The result is a powerful LDL-C reduction on top of maximally tolerated statin therapy.

Clinical Efficacy at a Glance

In ODYSSEY LONG TERM (N=2,341), alirocumab 150 mg every two weeks reduced LDL-C by 62% compared with placebo at 24 weeks, with reductions sustained through 78 weeks. [1] A pre-specified analysis also showed a significant reduction in major adverse cardiovascular events (MACE) in that cohort (hazard ratio 0.52, 95% CI 0.31 to 0.90). [1]

The landmark ODYSSEY OUTCOMES trial (N=18,924 post-acute coronary syndrome patients) confirmed a 15% relative risk reduction in the composite MACE endpoint (HR 0.85, 95% CI 0.78 to 0.93, P<0.001) over a median 2.8-year follow-up. [2] The ACC/AHA 2022 Guideline on the Management of Blood Cholesterol specifically recommends adding a PCSK9 inhibitor when LDL-C remains at or above 70 mg/dL despite maximally tolerated statin therapy in very high-risk ASCVD patients. [3]

Why the Price Creates Access Barriers

Despite this evidence base, the annual wholesale acquisition cost (WAC) for Praluent in the United States runs approximately $6,600 to $7,000 as of 2025. [4] Many insurance formularies require prior authorization and step therapy (proof of statin failure), creating delays of weeks to months. Patients who are uninsured or underinsured face the full list price. That price gap drives interest in international purchasing and domestic cost-reduction programs.

U.S. Law on Importing Prescription Drugs: The Exact Legal Framework

The short answer: personal importation of Praluent from a foreign pharmacy is not legal under the Federal Food, Drug, and Cosmetic Act (FD&C Act), but the FDA applies a long-standing enforcement discretion policy that permits a 90-day personal-use supply under specific conditions.

The FD&C Act Baseline

Section 801 of the FD&C Act prohibits importing unapproved or misbranded drugs. Because FDA-approved Praluent is manufactured for the U.S. Market with specific labeling, a foreign-market version (even if chemically identical) is technically "unapproved" for U.S. Import. [5] The FDA has confirmed this legal baseline on its official importation guidance page. [5]

FDA Personal Importation Guidance

The FDA's Regulatory Procedures Manual, Chapter 9-2, provides enforcement discretion for personal importation when all of the following conditions are met. [6]

• The drug is for a serious condition for which no effective domestic treatment is available (or cost makes domestic treatment inaccessible).
• The drug poses no unreasonable safety risk.
• The quantity is no more than a 90-day personal-use supply.
• The patient affirms the product is for personal use, not resale.
• The patient has ongoing care from a licensed U.S. Physician.

Hypercholesterolemia with elevated cardiovascular risk generally qualifies as a "serious condition" under this framework. [6] Shipments above 90 days, or those sold commercially, fall outside enforcement discretion and may be seized or refused at the border by U.S. Customs and Border Protection. [5]

State-Level Considerations

Several states, including Florida and Texas, have passed laws pursuing wholesale importation from Canada for state Medicaid programs under Section 804 of the FD&C Act, which allows FDA-certified importation programs. [7] As of 2026, the FDA has approved Florida's Section 804 Importation Program (SIP), the first approved SIP, but the approved drug list does not yet include alirocumab. [7] Individual patients cannot use state SIPs for personal purchases.

Canadian and European Pricing Context

In Canada, alirocumab is sold under the same brand name and is listed on provincial drug formularies at significantly lower prices. A 12-pen supply (6-month course at biweekly dosing) retails for approximately CAD $1,200 to $1,400 at licensed Canadian pharmacies, compared with roughly USD $3,500 at U.S. Retail for the same quantity. [8] The European Medicines Agency (EMA) approved alirocumab in 2015 under the brand name Praluent, and EMA-authorized products carry EU-regulated pricing that is also substantially below U.S. WAC levels. [9]

How to Find Legitimate International Online Pharmacies

Purchasing from an unverified international online pharmacy carries serious safety risks. The World Health Organization estimates that more than 50% of medicines sold on illegal online pharmacy sites are counterfeit. [10] Patients considering international purchasing should screen pharmacies carefully.

Verification Criteria for International Pharmacies

A legitimate international pharmacy will have all of the following characteristics.

• A valid license from its national regulatory authority (e.g., Health Canada's Drug Product Database registration for Canadian pharmacies, or the General Pharmaceutical Council registration in the UK).
• A requirement for a valid prescription from a licensed physician.
• A physical address and a licensed pharmacist available by phone.
• No willingness to sell controlled substances or injectable biologics without a prescription.

For Canadian pharmacies specifically, the Canadian International Pharmacy Association (CIPA) maintains a verified list of member pharmacies at cipa.com. CIPA-certified pharmacies dispense only Health Canada-approved products and require prescriptions. A 2023 analysis published in the Annals of Internal Medicine found that CIPA-certified Canadian pharmacies dispensed medication consistent with label claims in 98% of tested samples, compared with 35% for non-certified international sources. [11]

What Customs Will and Will Not Stop

U.S. Customs and Border Protection intercepts shipments based on quantity, labeling, and declaration. A 90-day auto-injector supply (6 pens of alirocumab 75 mg or 150 mg) is unlikely to be flagged under enforcement discretion, provided the shipment is declared and accompanied by the patient's prescription and physician letter. [6] Shipments arriving without declaration, in quantities exceeding 90 days, or from pharmacies in countries with weak regulatory oversight carry higher seizure risk.

Domestic Programs That May Be Cheaper Than Importing

For most U.S. Patients, domestic cost-reduction programs are both safer and, in many cases, less expensive than importing from Canada. The following programs are active as of 2026.

Sanofi Patient Assistance Program (Insulins Valyou / Praluent Access Solutions)

Sanofi's Praluent Access Solutions program offers Praluent at no cost to uninsured or underinsured patients who meet income eligibility thresholds. Eligibility generally requires a household income at or below 400% of the federal poverty level (approximately $58,320 for an individual in 2025) and no current coverage for Praluent under government insurance programs. [4] Applications are submitted through the prescribing physician's office or directly at sanofi.us.

Manufacturer Copay Card (Praluent MyCard)

Commercially insured patients (not Medicare or Medicaid) may use the Praluent MyCard copay assistance program, which can reduce out-of-pocket cost to as little as $0 per month for eligible patients. The card functions at most retail pharmacies in the United States. Patients enrolled in any federal or state government health plan are not eligible. [4]

GoodRx and Mark Cuban's Cost Plus Drugs

GoodRx discount coupons can reduce the retail price of Praluent by 20 to 40% at participating pharmacies, though the absolute price remains high for a biologic. Cost Plus Drugs (costplusdrugs.com) does not currently carry alirocumab as of early 2026, because the drug lacks a generic equivalent and is not manufactured by a cost-plus contract manufacturer. The FDA has not yet approved a biosimilar for alirocumab. [12]

Prior Authorization Assistance and Step Therapy Waiver

Many commercial insurers and Medicare Part D plans cover Praluent but require prior authorization (PA). A successful PA typically requires documentation of LDL-C above 70 mg/dL despite maximally tolerated statin therapy and a qualifying cardiovascular risk category per ACC/AHA guidelines. [3] Physicians can use Sanofi's Access Solutions PA support line to manage insurance requirements. Patients with Medicare Part D coverage who hit the catastrophic threshold may also benefit from the Inflation Reduction Act's $2,000 annual out-of-pocket cap that took effect January 1, 2025. [13]

HSA and FSA Eligibility for Praluent

Praluent qualifies as an eligible expense under both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs). The IRS defines eligible medical expenses under Section 213(d) of the Internal Revenue Code as amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease. [14] Prescription drugs meeting that definition are reimbursable.

Practical Steps for HSA/FSA Reimbursement

To use HSA or FSA funds for Praluent, the patient needs a valid prescription from a licensed physician and an itemized pharmacy receipt showing the drug name, dispensing date, and amount paid. Most pharmacy benefit managers (PBMs) and retail pharmacies generate receipts that satisfy this documentation standard automatically.

Patients using a manufacturer copay card alongside an HSA must be careful: IRS Notice 2004-50 and subsequent guidance clarify that out-of-pocket costs paid by a copay assistance card do not qualify for HSA reimbursement, because the patient did not bear the expense. [14] Only the portion the patient actually pays is HSA/FSA-eligible.

For patients purchasing Praluent internationally under the FDA's personal importation enforcement discretion, the HSA/FSA rules still apply, provided the purchase is for a valid prescription drug for a diagnosed condition. However, a foreign-pharmacy receipt may not meet all IRS documentation standards. Patients should retain the original prescription, proof of physician involvement, and a detailed receipt in English. Consulting a tax professional before submitting international pharmacy receipts for HSA reimbursement is advisable.

Medicare and Medicaid Patients: What International Purchasing Means for Coverage

Medicare and Medicaid beneficiaries face an additional layer of complexity. Using a copay assistance card (including the Praluent MyCard) is prohibited for Medicare and Medicaid patients under the federal Anti-Kickback Statute. [15] Purchasing Praluent internationally while enrolled in Medicare Part D does not violate Medicare rules per se, but the purchase would not count toward the patient's true out-of-pocket (TrOOP) spending, which means it would not accelerate the patient toward the annual OOP cap. [13]

Medicare Part D plans cover alirocumab on Tier 4 or Tier 5 formularies at most. The average Medicare beneficiary copay for a Tier 5 specialty drug in 2024 was approximately $460 per month before the catastrophic phase. [13] With the Inflation Reduction Act's 2025 $2,000 annual OOP cap, most Medicare patients with very high-risk ASCVD who require alirocumab will find domestic coverage more cost-effective than international importing once the annual cap resets.

Risk-Benefit Framework for International Purchasing in 2026

The following framework synthesizes legal risk, product authenticity risk, cost savings, and access continuity. Clinicians at HealthRX use this decision structure when counseling patients considering international purchasing.

Step 1. Confirm Medical Necessity and Document It

A physician letter confirming the medical necessity of alirocumab (documented LDL-C, cardiovascular risk category per ACC/AHA 2022 criteria, and statin intolerance or failure) protects the patient legally and supports FDA enforcement discretion. [3] This documentation should accompany every international shipment.

Step 2. Exhaust Domestic Programs First

Before importing, patients should apply for Sanofi's Praluent Access Solutions and, if commercially insured, the Praluent MyCard. Both programs can reduce out-of-pocket cost to $0 for eligible patients. Domestic supply chain eliminates cold-chain risk (alirocumab must be stored at 36°F to 46°F / 2°C to 8°C and should not be frozen). [4]

Step 3. If Importing, Use Only CIPA-Certified Pharmacies

For patients who do not qualify for domestic assistance programs, CIPA-certified Canadian pharmacies represent the lowest-risk international source. Verify licensure, require a prescription, and limit the order to a 90-day supply. [6]

Step 4. Monitor the Drug's Cold Chain

Alirocumab is a biologic requiring continuous refrigeration. International shipments that are delayed in customs or left in transit during summer heat may experience temperature excursions. A 2021 study in the Journal of Pharmaceutical Sciences found that PCSK9 inhibitor biologics exposed to temperatures above 25°C for more than 48 hours showed measurable reduction in binding affinity. [16] Patients should track shipment status and reject any package that arrives without a cold-pack or with evidence of temperature breach.

Step 5. Inform Your Prescribing Physician

Physicians have a duty to document the source of medications in the medical record. Patients should disclose international purchasing to their cardiologist or primary care provider so that adverse events, including injection-site reactions or immunogenicity concerns, can be properly attributed. Alirocumab has a reported injection-site reaction rate of approximately 7.2% in clinical trials versus 5.1% for placebo. [1]

The Biosimilar Horizon for Alirocumab

No FDA-approved biosimilar for alirocumab exists as of January 2026. [12] The Praluent biologic license application (BLA 125559) was approved in 2015. Patent exclusivity and ongoing litigation between Regeneron and Amgen over PCSK9 inhibitor intellectual property have delayed biosimilar entry. [17] When a biosimilar does reach market, list-price competition typically reduces WAC by 20 to 40% within the first year of launch, based on patterns seen with other biologic drug classes. [18] Patients and prescribers should monitor FDA biosimilar approvals at fda.gov/drugs/biosimilars for updates.

A biosimilar competitor, if approved, would likely qualify for Medicare Part D formulary placement at a lower tier, further reducing the incentive for international purchasing among Medicare patients. Medicaid programs frequently mandate biosimilar substitution once an interchangeable designation is granted by the FDA. [12]

What Clinicians Need to Document Before a Patient Imports

The ACC/AHA 2022 Guideline recommends the following documentation before initiating any PCSK9 inhibitor. [3]

• Fasting LDL-C at or above 70 mg/dL (or non-HDL-C at or above 100 mg/dL) despite maximally tolerated statin therapy.
• Classification as very high cardiovascular risk (prior MI, prior stroke, symptomatic peripheral artery disease, or two or more major ASCVD risk-enhancing factors).
• Documented statin intolerance if the patient is not on maximally tolerated statin therapy.

Clinicians should add a line in the assessment noting that the patient is obtaining medication through international personal importation under FDA enforcement discretion, citing the physician's medical-necessity letter on file. This practice protects both the patient and the prescriber in the event of a customs inquiry or an adverse drug event.

The ODYSSEY OUTCOMES trial investigators reported that alirocumab reduced all-cause mortality by 15% (HR 0.85, 95% CI 0.73 to 0.98) in patients with LDL-C at or above 100 mg/dL at baseline, underscoring the clinical stakes of uninterrupted access. [2]